JP2011528896A5 - - Google Patents

Download PDF

Info

Publication number
JP2011528896A5
JP2011528896A5 JP2011519186A JP2011519186A JP2011528896A5 JP 2011528896 A5 JP2011528896 A5 JP 2011528896A5 JP 2011519186 A JP2011519186 A JP 2011519186A JP 2011519186 A JP2011519186 A JP 2011519186A JP 2011528896 A5 JP2011528896 A5 JP 2011528896A5
Authority
JP
Japan
Prior art keywords
tuberculosis
prevention
protein sequence
treatment
rv2386c protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011519186A
Other languages
English (en)
Japanese (ja)
Other versions
JP5981138B2 (ja
JP2011528896A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/059585 external-priority patent/WO2010010179A1/en
Publication of JP2011528896A publication Critical patent/JP2011528896A/ja
Publication of JP2011528896A5 publication Critical patent/JP2011528896A5/ja
Application granted granted Critical
Publication of JP5981138B2 publication Critical patent/JP5981138B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011519186A 2008-07-25 2009-07-24 結核Ｒｖ２３８６ｃタンパク質、組成物およびその使用 Expired - Fee Related JP5981138B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8369908P 2008-07-25 2008-07-25
US61/083,699 2008-07-25
PCT/EP2009/059585 WO2010010179A1 (en) 2008-07-25 2009-07-24 The tuberculosis rv2386c protein, compositions and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015134587A Division JP6104326B2 (ja) 2008-07-25 2015-07-03 結核Ｒｖ２３８６ｃタンパク質、組成物およびその使用

Publications (3)

Publication Number Publication Date
JP2011528896A JP2011528896A (ja) 2011-12-01
JP2011528896A5 true JP2011528896A5 (enExample) 2012-09-06
JP5981138B2 JP5981138B2 (ja) 2016-08-31

Family

ID=41227131

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011519186A Expired - Fee Related JP5981138B2 (ja) 2008-07-25 2009-07-24 結核Ｒｖ２３８６ｃタンパク質、組成物およびその使用
JP2015134587A Expired - Fee Related JP6104326B2 (ja) 2008-07-25 2015-07-03 結核Ｒｖ２３８６ｃタンパク質、組成物およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015134587A Expired - Fee Related JP6104326B2 (ja) 2008-07-25 2015-07-03 結核Ｒｖ２３８６ｃタンパク質、組成物およびその使用

Country Status (23)

Country Link
US (4) US20110206712A1 (enExample)
EP (1) EP2315834B1 (enExample)
JP (2) JP5981138B2 (enExample)
KR (1) KR20110049834A (enExample)
CN (2) CN102165064B (enExample)
AU (1) AU2009273132B2 (enExample)
BR (1) BRPI0916704A2 (enExample)
CA (1) CA2731547C (enExample)
CO (1) CO6351811A2 (enExample)
CY (1) CY1121632T1 (enExample)
DK (1) DK2315834T3 (enExample)
EA (1) EA201100070A1 (enExample)
ES (1) ES2685498T3 (enExample)
HR (1) HRP20181353T1 (enExample)
HU (1) HUE039159T2 (enExample)
IL (1) IL210589A (enExample)
LT (1) LT2315834T (enExample)
MX (1) MX2011000982A (enExample)
PL (1) PL2315834T3 (enExample)
PT (1) PT2315834T (enExample)
SI (1) SI2315834T1 (enExample)
UA (1) UA107329C2 (enExample)
WO (1) WO2010010179A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007106536A2 (en) * 2006-03-14 2007-09-20 Oregon Health & Science University Methods for producing an immune response to tuberculosis
US20110189217A1 (en) * 2008-06-26 2011-08-04 Barry Michael A Methods and materials for producing immune responses against polypeptides involved in antibiotic resistance
HRP20181353T1 (hr) * 2008-07-25 2018-10-19 Glaxosmithkline Biologicals S.A. Tuberkulozni protein rv2386c, njegovi pripravci i upotreba
NO2315597T3 (enExample) 2008-07-25 2018-01-20
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
US20140349320A1 (en) * 2011-12-15 2014-11-27 The Trustees Of The University Of Pennsylvania Using Adaptive Immunity to Detect Drug Resistance
CN107478849B (zh) * 2013-05-31 2019-08-20 中国医学科学院病原生物学研究所 用于结核病诊断和预防的蛋白
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
WO2016024129A1 (en) * 2014-08-15 2016-02-18 Oxford Immunotec Limited Mycobacterium tuberculosis proteins
CN105572352B (zh) * 2016-02-17 2017-07-28 遵义医学院附属医院 一组结核潜伏感染诊断标志物及其用途
CA3045952A1 (en) 2016-12-07 2018-06-14 Glaxosmithkline Biologicals Sa Novel process
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600652B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel compositions
JP2021504424A (ja) 2017-12-01 2021-02-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
CN109234414B (zh) * 2018-06-29 2022-05-17 周琳 结核分枝杆菌的对氨基水杨酸耐药性诊断标志物及其应用
CN108950031A (zh) * 2018-06-29 2018-12-07 周琳 结核分枝杆菌的利福平耐药性诊断标志物及其应用
CN108866213A (zh) * 2018-06-29 2018-11-23 周琳 结核分枝杆菌利福平耐药性诊断标志物及其应用
WO2020245207A1 (en) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification
WO2020249756A1 (en) * 2019-06-14 2020-12-17 Statens Serum Institut Fusion proteins for tuberculosis vaccines
CN112457410B (zh) * 2020-11-05 2023-04-07 迈克生物股份有限公司 用于结核分枝杆菌感染检测的抗原组合物
DE202022102137U1 (de) 2022-04-21 2022-04-28 Damayanthi Dalu Eine neue Zusammensetzung zur Behandlung von Tuberkulose
CN115073612B (zh) * 2022-06-22 2024-09-27 宁夏大学 一种结核分枝杆菌Zera-71cA蛋白纳米颗粒、制备方法及其用途
CN115725607B (zh) * 2022-07-14 2023-11-28 山东第一医科大学附属省立医院(山东省立医院) 一种鼻疽诺卡菌的致病靶基因及其应用
WO2026037283A1 (zh) * 2024-08-16 2026-02-19 广州派诺生物技术有限公司 一种用于预防和治疗结核分枝杆菌感染的疫苗及其制备方法
CN120058854A (zh) * 2025-03-05 2025-05-30 北京知筹科技有限公司 一种调节低密度脂蛋白受体相关蛋白（lrp）的多肽及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6613881B1 (en) 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
BR9909472A (pt) 1998-04-07 2001-09-11 Corixa Corp Polipeptìdeo purificado, processo para prevenir tuberculose, e, composição farmacêutica
WO2001062893A2 (en) 2000-02-25 2001-08-30 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
PT2133100E (pt) 2000-06-20 2012-01-11 Corixa Corp Antigénio mtb32a de mycobacterium tuberculosis com um local activo inactivado e suas proteínas de fusão
US20040121322A9 (en) 2001-02-22 2004-06-24 Cole Stewart T. Comparative mycobacterial genomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
AU2003213118A1 (en) 2002-02-15 2003-09-09 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US20030236393A1 (en) 2002-03-22 2003-12-25 United States Of America Dept Of Vetrans Affairs Virulence genes of M. marinum and M. tuberculosis
US7424370B2 (en) 2004-02-06 2008-09-09 Council Of Scientific And Industrial Research Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential
PT2426141E (pt) * 2005-04-29 2014-11-25 Glaxosmithkline Biolog Sa Método para prevenção ou tratamento de uma infecção por m. tuberculosis
WO2008007942A1 (en) 2006-07-10 2008-01-17 Het Nederlands Kanker Instituut Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof
CN103550764A (zh) 2007-03-02 2014-02-05 葛兰素史密丝克莱恩生物有限公司 疫苗组合物及其在刺激免疫反应中的用途
WO2010010178A1 (en) 2008-07-25 2010-01-28 Glaxosmithkline Biologicals S.A The tuberculosis rv2707c protein, compositions and uses thereof
NO2315597T3 (enExample) 2008-07-25 2018-01-20
EP2315773B1 (en) 2008-07-25 2016-08-24 GlaxoSmithKline Biologicals S.A. Polypeptides, polynucleotides and compositions for use in the treatment of latent tubeculosis
HRP20181353T1 (hr) * 2008-07-25 2018-10-19 Glaxosmithkline Biologicals S.A. Tuberkulozni protein rv2386c, njegovi pripravci i upotreba
EP2421557B1 (en) 2009-04-24 2018-12-05 Statens Serum Institut A tuberculosis tb vaccine to prevent reactivation
US8367055B2 (en) 2009-05-14 2013-02-05 Wisconsin Alumni Research Foundation Immunogenic compositions against tuberculosis
LT2528621T (lt) 2010-01-27 2016-12-12 Glaxosmithkline Biologicals S.A. Modifikuoti tuberkuliozės antigenai

Similar Documents

Publication Publication Date Title
JP2011528895A5 (enExample)
JP2011528897A5 (enExample)
JP2012126742A5 (enExample)
JP2012136541A5 (enExample)
JP2013172734A5 (enExample)
JP2013231081A5 (enExample)
HRP20161458T1 (hr) Polipeptidi, polinukleotidi i pripravci namijenjeni upotrebi u liječenju latentne tuberkuloze
CA2818990C (en) Designed repeat proteins binding to serum albumin
JP2011136997A5 (enExample)
JP2011500073A5 (enExample)
JP2010512795A5 (enExample)
JP2014507144A5 (ja) 慢性ｂ型肝炎感染症のための酵母系免疫療法組成物
JP2008536483A5 (enExample)
FI3581650T3 (fi) IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi
JP2014530220A5 (enExample)
JP2008530245A5 (enExample)
JP2014529399A5 (enExample)
JP2015096557A5 (enExample)
JP2009213477A5 (enExample)
JP2015510393A5 (enExample)
JP2010503396A5 (enExample)
JP2011530309A5 (enExample)
JP2015517489A5 (enExample)
JP2005516885A5 (enExample)
JP2011511805A5 (enExample)